Organon (OGN) closed the most recent trading day at $9.95, moving +1.53% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 1.11%. Elsewhere, the Dow saw an upswing of 1.19%, while the tech-heavy Nasdaq appreciated by 1.43%.
The stock of pharmaceutical company has risen by 12.77% in the past month, leading the Medical sector's gain of 2.14% and the S&P 500's gain of 3.92%.
Market participants will be closely following the financial results of Organon in its upcoming release. The company's upcoming EPS is projected at $0.93, signifying a 16.96% drop compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $1.55 billion, down 3.35% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $3.83 per share and a revenue of $6.24 billion, signifying shifts of -6.81% and -2.48%, respectively, from the last year.
Investors should also pay attention to any latest changes in analyst estimates for Organon. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Organon presently features a Zacks Rank of #2 (Buy).
In terms of valuation, Organon is currently trading at a Forward P/E ratio of 2.56. This represents a discount compared to its industry average Forward P/E of 15.78.
We can additionally observe that OGN currently boasts a PEG ratio of 0.97. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The average PEG ratio for the Medical Services industry stood at 1.35 at the close of the market yesterday.
The Medical Services industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 74, placing it within the top 31% of over 250 industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Organon & Co. (OGN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
